On the recordSeptember 24, 2019
This committee has a history of working in a bipartisan manner to improve generic and biosimilar competition.
Source
congress.govThis committee has a history of working in a bipartisan manner to improve generic and biosimilar competition.
Burgess highlights the committee's past bipartisan efforts to enhance drug competition.
Share
More from Michael Burgess
I will simply underscore the fact that entry- level chemists at the EPA are hired at much higher than the GSA rate. These are not highly sought-after scientists. These are entry-level applicants, and there is no shortage of applicants for…
I never expected that CMMI was actually going to deliver the cost savings that was promised.
This is a national emergency. This is something we have got to address and save Americans, 200 every day.
I led a letter to the FDA asking them to reclassify naloxone to where you could get it without a prescription.